Theravance board adds Slater
Executive Summary
Former HHS Assistant Secretary for Health Eve Slater has joined Theravance's board of directors, the firm announced Dec. 12. Before joining HHS, Slater was Merck VP-external policy & public affairs. Slater rejoins former Merck CEO and current Theravance Chairman Roy Vagelos on the board. Slater serves on the boards of a number of other firms, including Vertex and VaxGen (1"The Pink Sheet" July 18, 2005, In Brief)...
You may also be interested in...
Ex-HHS official joins VaxGen board
Eve Slater joins VaxGen board of directors. Slater served as assistant secretary for health and chief policy advisor to former HHS Secretary Tommy Thompson. Before joining HHS, she was Merck's VP-external policy & public affairs. Slater also serves on the board of data management solutions firm Phase Forward and Vertex Pharmaceuticals (1"The Pink Sheet" June 27, 2005, In Brief)...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.